Loading…
Annovis Bio, Inc. is projected to rise to $2.64 by 2027, a +32% move from its current price of $2.01. ANVS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.92 | $2.01 | $2.10 | -0.06% |
| May 30 | $1.89 | $2.01 | $2.13 | -0.11% |
| May 31 | $1.86 | $2.01 | $2.16 | -0.17% |
| Jun 1 | $1.84 | $2.01 | $2.19 | -0.23% |
| Jun 2 | $1.82 | $2.00 | $2.21 | -0.28% |
| Jun 3 | $1.80 | $2.00 | $2.23 | -0.34% |
| Jun 4 | $1.79 | $2.00 | $2.25 | -0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.79 | $2.00 | $2.25 | -0.40% |
| Week 2 | $1.70 | $1.99 | $2.35 | -0.79% |
| Week 3 | $1.63 | $1.99 | $2.42 | -1.18% |
| Week 4 | $1.57 | $1.98 | $2.49 | -1.57% |
| Week 5 | $1.52 | $1.97 | $2.55 | -1.96% |
| Week 6 | $1.48 | $1.96 | $2.60 | -2.35% |
| Week 7 | $1.44 | $1.95 | $2.65 | -2.74% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Annovis Bio, Inc. is a clinical stage drug platform company that develops drugs to treat neurodegeneration in the United States.
The company’s lead product candidate is Buntanetap, which is in phase 3 to treat Alzheimer's disease, as well as in open-label phase 3 to treat Parkinson’s disease.
It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of Alzheimer’s disease and dementia.
Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
ANVS is trading at $2.01 per share, with a market capitalization of $85.51M. Its rank is 4268.
The price outlook implied by the yearly forecast shows a long horizon of upside, with 2026 avg $2.01, 2027 avg $2.64, 2028 avg $2.78, 2029 avg $2.69, 2030 avg $2.74, 2040 avg $4.36 and 2050 avg $8.22.
A major floor 30.8% below — a decisive break under it would weaken the trend.
The nearest floor, 13.4% below — buyers have tended to step in here.
The nearest ceiling, 19.4% above — a clean break opens room to run.
A major ceiling 52.2% above — clearing it would confirm fresh momentum.
Key ANVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ANVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.10 | Sell | $2.08 | Sell |
| MA 10 | $2.09 | Sell | $2.10 | Sell |
| MA 20 | $2.14 | Sell | $2.10 | Sell |
| MA 50 | $2.10 | Sell | $2.18 | Sell |
| MA 100 | $2.46 | Sell | $2.37 | Sell |
| MA 200 | $2.62 | Sell | $2.68 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.06 | Neutral |
| Stoch RSI (14) | 18.46 | Buy |
| CCI (20) | -66.67 | Neutral |
| Williams %R (14) | -84.44 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -11.84 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 15.56 | Buy |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 0.10 | Buy |
| Ultimate (7,14,28) | 43.91 | Neutral |
| Momentum (10) | -0.27 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 2.13 | Sell |
| ADX (14) | 11.63 | Neutral |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is BEARISH.
RSI(14) is 50, and the moving averages place the price around key levels: SMA50 at $2.10 and SMA200 at $2.62.
Support is at $1.74 and resistance at $2.40, with a 30-day price range from $1.51 to $2.67.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.59 | $2.01 | $2.63 | 0% | Neutral | |
| $1.98 | $2.64 | $3.81 | +32% | Bullish | |
| $1.99 | $2.78 | $4.22 | +38% | Bullish | |
| $1.85 | $2.69 | $4.25 | +34% | Bullish | |
| $1.81 | $2.74 | $4.47 | +36% | Bullish | |
| $1.59 | $2.48 | $4.17 | +23% | Bullish | |
| $1.67 | $2.69 | $4.65 | +34% | Bullish | |
| $1.85 | $3.07 | $5.42 | +53% | Bullish | |
| $1.97 | $3.36 | $6.07 | +67% | Bullish | |
| $2.37 | $4.15 | $7.65 | +106% | Bullish | |
| $2.18 | $4.36 | $8.73 | +117% | Bullish | |
| $3.70 | $8.22 | $18.55 | +309% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.59 | $2.01 | $2.39 | +0.00% |
| June 2026 | $1.69 | $2.01 | $2.46 | -0.14% |
| July 2026 | $1.58 | $1.91 | $2.39 | -4.90% |
| August 2026 | $1.59 | $1.94 | $2.47 | +1.80% |
| September 2026 | $1.61 | $1.97 | $2.55 | +1.59% |
| October 2026 | $1.50 | $1.86 | $2.43 | -5.63% |
| November 2026 | $1.47 | $1.83 | $2.41 | -1.69% |
| December 2026 | $1.57 | $1.97 | $2.63 | +7.73% |
Click any year to see its month-by-month ANVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ANVS price prediction for 2026 points to an average of $2.01 (low $1.59, high $2.63) — a potential gain of 0% on today's $2.01. A consolidation phase looks the most probable path here.
In 2027, ANVS is projected to trade between $1.98 and $3.81, averaging $2.64 — a potential gain of +32% from today's $2.01. That is up +32% on the projected 2026 average. Momentum favours further upside here.
Annovis Bio, Inc.'s 2028 outlook centres on $2.78, within a $1.99 to $4.22 range. That is up +5% on the projected 2027 average. That marks a +38% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ANVS could reach as high as $4.25, with a base case around $2.69 and support toward $1.85 — roughly +34% from $2.01. Momentum favours further upside here.
Expect ANVS to range from $1.81 to $4.47 through 2030. The $2.74 average target implies a +36% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ANVS price prediction for 2031 points to an average of $2.48 (low $1.59, high $4.17) — a potential gain of +23% on today's $2.01. Momentum favours further upside here.
In 2032, ANVS is projected to trade between $1.67 and $4.65, averaging $2.69 — a potential gain of +34% from today's $2.01. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Annovis Bio, Inc.'s 2033 outlook centres on $3.07, within a $1.85 to $5.42 range. That is up +14% on the projected 2032 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2034, ANVS could reach as high as $6.07, with a base case around $3.36 and support toward $1.97 — roughly +67% from $2.01. Buyers look set to stay in control over this stretch.
Expect ANVS to range from $2.37 to $7.65 through 2035. The $4.15 average target implies a +106% move from current prices. That is up +23% on the projected 2034 average. Momentum favours further upside here.
The ANVS price prediction for 2040 points to an average of $4.36 (low $2.18, high $8.73) — a potential gain of +117% on today's $2.01. Buyers look set to stay in control over this stretch.
In 2050, ANVS is projected to trade between $3.70 and $18.55, averaging $8.22 — a potential gain of +309% from today's $2.01. That is up +89% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ANVS today (≈ 497.512438 ANVS) could be worth
$4,091.61
+$3,091.61 (+309%) by 2050 · US Dollar
Based on the average projected ANVS price of $8.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ANVSwould be worth at today's price.
$1,000 invested in ANVS on May 27, 2025 (≈ 490.196088 ANVS) would be worth
$985.29
-$14.71 (-1.5%) today · 0.99× · US Dollar
Based on a ANVS entry price of $2.04 vs. today's $2.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.04 | $985.29 | -1.5% |
| 1 month ago | $1.89 | $1,063.49 | +6.3% |
| 3 months ago | $2.77 | $725.63 | -27.4% |
| 6 months ago | $5.1 | $394.12 | -60.6% |
| 1 year ago | $2.04 | $985.29 | -1.5% |
| All time (5.0y) ago | $57.47 | $34.97 | -96.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ANVS forecast.
Our base-case forecast reaches $4.00 around 2035.
Implied market cap at $4.00: $170.17M
The multi-year forecast shows a bullish trajectory with rising average prices over time. In 2030 the avg price is $2.74 with a max of $4.47 and a min of $1.81, and the forecast assigns a 36.2 to the price path; sentiment is bullish in the near-to-mid term.
The horizon includes further upside: in 2040 the avg is $4.36 with a max of $8.73 and a min of $2.18, with an estimated ROI of 116.8 and bullish sentiment.
By 2050 the avg is $8.22 with a max of $18.55 and a min of $3.70, with an estimated ROI of 309.2 and bullish sentiment. These are estimates, not guarantees, and outcomes depend on many factors beyond the numbers.
Tap a question to reveal the answer.
The 2030 forecast shows avg $2.74, min $1.81, max $4.47, with ROI 36.2 and bullish sentiment.
Forecasts indicate a bullish path from 2027 onward, with rising averages and ROIs, including avg $8.22 by 2050 and ROI 309.2.
Yes. The 2033 max is $5.42, 2034 max $6.07, and 2035 max $7.65, indicating potential upside above $5 in the coming years.
Current price is $2.01 and market cap is $85.51M.
The 2040 forecast shows avg $4.36, max $8.73, min $2.18, with ROI 116.8 and bullish sentiment.
Annovis Bio, Inc. Community Discussion
0Share your Annovis Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.